Vigabatrin For Treatment of Methamphetamine Dependence: A Phase II Study

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/086/30/09

Funding

  • Catalyst Pharmaceutical Partners Inc: $27,090.00